Posts by: Alejandra Viviescas, PhD

News

A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the ... Read more

August 14, 2019

Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC

News

Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The ... Read more

August 9, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients ... Read more

June 14, 2019June 14, 2019

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

News

The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial ... Read more

June 3, 2019

OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells

News

PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be ... Read more

Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Immix Cleared to Expand Phase 1/2a Trial of IMX-110 to US Sites

Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells

Pin It on Pinterest